Menu

Close

識步處

斷定風險狀況 

識別COVID-19的病徵

治療方案 

心路歷程分享

COVID-19新冠確診者心路歷程及經驗心得分享

感染新冠肺炎,對患者的生理及心理都可以造成很大影響;而對於身邊的照顧者,亦會構成不少壓力。不少人在自己或家人感染新冠肺炎時,擔心病情之餘,又未必了解有效的治療方法,難免感到徬徨。其實只要在確診新冠肺炎後採取合適的治療,便可以更從容應對新冠肺炎病情。以下為大家分享作為關護者、高危一族及年長人士,在面對新冠肺炎時的症狀及過程等經驗及心得,讓大家更了解如何在確診新冠肺炎後,保護自己和家人。

新冠歷程經驗分享一:關護者

– Yanny

當我知道屋企人確診之後的確好擔心,但我都叫自己要先冷靜,先陪佢哋去搵醫生了解清楚佢哋健康狀況,好彩病毒無造成好大嘅風險,於是提佢哋多休息,家人康復之後都無太多後遺症。雖然新冠已經演變為大流行病,但我哋都要時刻提高警覺,主動「識.步.處」,做好準備同病毒共存!

新冠歷程經驗分享二:高危一族

– 泰山

確診新冠時最辛苦就係不停咳,由於我本身有高血壓同膽固醇偏高,引起併發症嘅風險比較高 1,所以有繼續留意住自己健康狀況,最緊要「識.步.處」,做好準備同病毒共存!

新冠歷程經驗分享三:年長人士

– 波姐

我都曾經確診過新冠,雖然症狀同感冒差不多,都唔敢掉以輕心,因為我哋年長人士,確診之後嘅風險唔可以忽視。當時我嘅家人建議我先同家庭醫生講番自己情況,再決定一下步點做,最後醫生都建議我可以留喺屋企,不過康復過後,都有啲氣促問題,需要調理番一段時間。所以提醒各位老友記,一旦確診,記得要「識.步.處」,做好準備同病毒共存!

不少人以為確診新冠肺炎後沒有任何有效的治療方法,只能等到相關症狀消退便會自然痊癒。現時「符合資格人士」確診後可獲處方由政府提供的新冠口服藥物。建議新冠肺炎確診者,尤其容易出現併發症的長期病患者及長者等高危人士,在確診後盡快求醫並接受適當的治療,以減低因新冠症狀而入院或出現嚴重併發症而死亡的風險。1

References: 1. People with Certain Medical Conditions and COVID-19 Risk Factors. CDC. Updated June 24, 2024. Available at: https://www.cdc.gov/covid/risk-factors/index.html. Accessed October 8, 2024.


識步處 Loading 斷定風險狀況 Loading 識別COVID-19的病徵 Loading 治療方案 Loading 心路歷程分享 Loading

©2024 Pfizer Inc. All rights reserved.

PP-C1D-HKG-0054 DEC 2024
Loading Sent
Loading Sent
LoadingReferencesReferences: 1. Clark A, Jit M, Warren-Gash C, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8(8):1003-1017. 2. COVID-19 treatment and medications. Centers for Disease Control and Prevention. Updated October 19, 2022. Accessed October 31, 2022. https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html 3. People with certain medical conditions. Centers for Disease Control and Prevention. Updated October 19, 2022. Accessed October 31, 2022. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html 4. Guan W-J, Liang W-H, Shi Y, et al. Chronic respiratory diseases and the outcomes of COVID-19: A nationwide retrospective cohort study of 39,420 cases. J Allergy Clin Immunol Pract. 2021;9(7):2645-2655.e14.